Zobrazeno 1 - 10
of 269
pro vyhledávání: '"Arnold G. Vulto"'
Publikováno v:
Health Research Policy and Systems, Vol 21, Iss 1, Pp 1-11 (2023)
Abstract Background The Belgian government has taken several measures to increase the uptake of biosimilars in past years. However, no formal evaluation of the impact of these measures has been made yet. This study aimed to investigate the impact of
Externí odkaz:
https://doaj.org/article/c732f63592704398a8b73ea2a8aaa4f1
Autor:
Qiushi Liang, Fabio Catalano, Eva C. Vlaar, Joon M. Pijnenburg, Merel Stok, Yvette van Helsdingen, Arnold G. Vulto, Ans T. van der Ploeg, Niek P. van Til, W.W.M. Pim Pijnappel
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 27, Iss , Pp 109-130 (2022)
Pompe disease is caused by deficiency of acid α-glucosidase (GAA), resulting in glycogen accumulation in various tissues, including cardiac and skeletal muscles and the central nervous system (CNS). Enzyme replacement therapy (ERT) improves cardiac,
Externí odkaz:
https://doaj.org/article/310576551caf4a2592416b696428e590
Autor:
Yannick Vandenplas, Steven Simoens, Philippe Van Wilder, Arnold G. Vulto, Florian Turk, Isabelle Huys
Publikováno v:
BMC Health Services Research, Vol 22, Iss 1, Pp 1-17 (2022)
Abstract Background A competitive market for off-patent biologicals leads to more affordable and high-quality healthcare. In recent years, Belgium has been characterized by its low use of biosimilars and by its shifts from off-patent biologicals towa
Externí odkaz:
https://doaj.org/article/59e1fc16f9ed4505adf3bff497d1bc28
Autor:
Qiushi Liang, Eva C. Vlaar, Fabio Catalano, Joon M. Pijnenburg, Merel Stok, Yvette van Helsdingen, Arnold G. Vulto, Wendy W.J. Unger, Ans T. van der Ploeg, W.W.M. Pim Pijnappel, Niek P. van Til
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 25, Iss , Pp 520-532 (2022)
Enzyme replacement therapy (ERT) is the current standard treatment for Pompe disease, a lysosomal storage disorder caused by deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA). ERT has shown to be lifesaving in patients with classic infa
Externí odkaz:
https://doaj.org/article/833c3541c3c74a63aa8c8bff6fa7155d
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background: Factors like the number of biosimilar competitors and competitive pricing strategies from originator companies may influence price competition and biosimilar uptake.Objective: The aim of this study was to analyze multiple facets of biosim
Externí odkaz:
https://doaj.org/article/64cf9e1e1f0643eaa31fa3a6dd3d95dd
Publikováno v:
Frontiers in Medicine, Vol 9 (2023)
BackgroundThe availability of biosimilar medicines in Southern European markets has allowed purchasing biologics at a lower cost for healthcare systems. However, the capacity to seize this cost-reduction opportunity in the long run depends on fosteri
Externí odkaz:
https://doaj.org/article/82e8d9267bb648f2aab034749a5501f0
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: The level of competition achieved following biosimilars market availability varies by country, care setting and molecule. Hence, biosimilars contribution to attaining price reductions and extended access to treatments can also vary.Object
Externí odkaz:
https://doaj.org/article/52c5da5bb0a5423aa8dd726a416a8179
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: By improving the affordability and accessibility of biologicals, biosimilar competition provides important benefits to healthcare systems and patients. In Belgium, biosimilar uptake and competition is limited compared to other European ma
Externí odkaz:
https://doaj.org/article/d0642ba99427483988e89756f00aa7c8
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
BackgroundBeyond evaluation and approval, European and national regulators have a key role in providing reliable information on biosimilars and the science underpinning their development, approval, and use.ObjectivesThis study aims to (i) review bios
Externí odkaz:
https://doaj.org/article/6dc74719abe448f38a2f130f5b660184
Autor:
Yannick Vandenplas, Liese Barbier, Steven Simoens, Philippe Van Wilder, Arnold G. Vulto, Isabelle Huys
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2022)
Background and objectives: Biosimilar medicines have been on the European market for 15 years. Despite the extensive and positive experience with biosimilars across Europe, their uptake remains limited in Belgium. One of the possible factors limiting
Externí odkaz:
https://doaj.org/article/dc5621398cce48eeaf008afdd0c8c935